BioRestorative Reports Positive Phase 2 Data for BRTX-100 in Chronic Lumbar Disc Disease
BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease MELVILLE, N.Y., March 30, 2026 — BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced blinded data from its […]
BioRestorative Reports Positive Phase 2 Data for BRTX-100 in Chronic Lumbar Disc Disease Read More »
